Leanne Cartee

791 total citations
27 papers, 646 citations indexed

About

Leanne Cartee is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Leanne Cartee has authored 27 papers receiving a total of 646 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Molecular Biology, 14 papers in Oncology and 6 papers in Cancer Research. Recurrent topics in Leanne Cartee's work include Cell death mechanisms and regulation (7 papers), Cancer-related Molecular Pathways (7 papers) and HER2/EGFR in Cancer Research (4 papers). Leanne Cartee is often cited by papers focused on Cell death mechanisms and regulation (7 papers), Cancer-related Molecular Pathways (7 papers) and HER2/EGFR in Cancer Research (4 papers). Leanne Cartee collaborates with scholars based in United States, Canada and Spain. Leanne Cartee's co-authors include Suguna Rachakonda, Gregory L. Kucera, Steven Grant, Paul Dent, Jorge A. Almenara, Roberto R. Rosato, Srikumar Chellappan, Rebecca Smith, Vicki Betts and Heidi Sankala and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

Leanne Cartee

26 papers receiving 624 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Leanne Cartee United States	14	357	226	99	94	82	27	646
F. M. Sirotnak United States	19	404 1.1×	301 1.3×	148 1.5×	59 0.6×	64 0.8×	42	1.0k
Anna Maria Trotta Italy	18	260 0.7×	424 1.9×	173 1.7×	63 0.7×	21 0.3×	35	1.1k
Atsushi Azuma Japan	16	453 1.3×	200 0.9×	65 0.7×	129 1.4×	119 1.5×	22	876
Casie Reed United States	14	632 1.8×	268 1.2×	103 1.0×	29 0.3×	16 0.2×	19	974
Christiane Schewe Germany	13	187 0.5×	204 0.9×	84 0.8×	37 0.4×	32 0.4×	18	571
Krzysztof Grzegorzewski United States	15	312 0.9×	214 0.9×	41 0.4×	12 0.1×	139 1.7×	34	862
Ming Chu United States	17	678 1.9×	259 1.1×	77 0.8×	150 1.6×	121 1.5×	49	1.2k
Earl G. Adams United States	13	360 1.0×	257 1.1×	72 0.7×	48 0.5×	53 0.6×	26	819
Elsa G. Barbacci United States	6	376 1.1×	396 1.8×	215 2.2×	15 0.2×	48 0.6×	8	767
Takeshi Kitazaki Japan	15	375 1.1×	582 2.6×	254 2.6×	105 1.1×	43 0.5×	37	896

Countries citing papers authored by Leanne Cartee

Since Specialization

Citations

This map shows the geographic impact of Leanne Cartee's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Leanne Cartee with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Leanne Cartee more than expected).

Fields of papers citing papers by Leanne Cartee

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Leanne Cartee. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Leanne Cartee. The network helps show where Leanne Cartee may publish in the future.

Co-authorship network of co-authors of Leanne Cartee

This figure shows the co-authorship network connecting the top 25 collaborators of Leanne Cartee. A scholar is included among the top collaborators of Leanne Cartee based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Leanne Cartee. Leanne Cartee is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Vinceneux, Armelle, Debbie Robbrecht, Karen A. Autio, et al.. (2025). Phase 1 study results of JNJ-78278343 (pasritamig) in metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 43(16_suppl). 5017–5017.

2.

Stein, Mark N., Laura Graham, Armelle Vinceneux, et al.. (2024). 1659TiP A phase I, first-in-human, open-label, multicenter, trial-in-progress of the safety, tolerability, and preliminary efficacy of JNJ-87189401 (PSMA-CD28 bispecific antibody) combined with JNJ-78278343 (KLK2-CD3 bispecific antibody) for advanced prostate cancer. Annals of Oncology. 35. S1000–S1000. 4 indexed citations

3.

Grilley‐Olson, Juneko E., Philippe L. Bédard, Angelica Fasolo, et al.. (2016). A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors. Investigational New Drugs. 34(6). 740–749. 64 indexed citations

4.

Spector, Neil L., Faith C. Robertson, Sarah Bacus, et al.. (2015). Lapatinib Plasma and Tumor Concentrations and Effects on HER Receptor Phosphorylation in Tumor. PLoS ONE. 10(11). e0142845–e0142845. 21 indexed citations

5.

Koch, Kevin M., Deborah A. Smith, Nikita Arya, et al.. (2015). Effect of lapatinib on oral digoxin absorption in patients. Clinical Pharmacology in Drug Development. 4(6). 449–453. 8 indexed citations

6.

Koch, Kevin M., Geraldine Ferron‐Brady, Leanne Cartee, et al.. (2014). Bioequivalence study with lapatinib powder for oral suspension and the original tablet formulation in cancer patients. Clinical Pharmacology in Drug Development. 4(3). 203–209. 5 indexed citations

7.

Koch, Kevin M., Young‐Hyuck Im, Sung‐Bae Kim, et al.. (2013). Effects of Esomeprazole on the Pharmacokinetics of Lapatinib in Breast Cancer Patients. Clinical Pharmacology in Drug Development. 2(4). 336–341. 23 indexed citations

8.

Devriese, Lot A., Kevin M. Koch, Marja Mergui‐Roelvink, et al.. (2013). Effects of low-fat and high-fat meals on steady-state pharmacokinetics of lapatinib in patients with advanced solid tumours. Investigational New Drugs. 32(3). 481–488. 41 indexed citations

9.

Rachakonda, Suguna & Leanne Cartee. (2004). Challenges in Antimicrobial Drug Discovery and the Potential of Nucleoside Antibiotics. Current Medicinal Chemistry. 11(6). 775–793. 101 indexed citations

10.

Stuyver, Lieven, Tamara R. McBrayer, Dirk Schürmann, et al.. (2004). Potent Antiviral Effect of Reverset™ in HIV-1-Infected Adults following a Single Oral Dose. Antiviral Therapy. 9(4). 529–536. 8 indexed citations

11.

Rosato, Roberto R., Jorge A. Almenara, Leanne Cartee, et al.. (2002). The cyclin-dependent kinase inhibitor flavopiridol disrupts sodium butyrate-induced p21WAF1/CIP1 expression and maturation while reciprocally potentiating apoptosis in human leukemia cells.. PubMed. 1(4). 253–66. 55 indexed citations

12.

Cartee, Leanne, Rebecca Smith, Yun Dai, et al.. (2002). Synergistic Induction of Apoptosis in Human Myeloid Leukemia Cells by Phorbol 12-Myristate 13-Acetate and Flavopiridol Proceeds via Activation of Both the Intrinsic and Tumor Necrosis Factor-Mediated Extrinsic Cell Death Pathways. Molecular Pharmacology. 61(6). 1313–1321. 36 indexed citations

13.

Cartee, Leanne, Rebecca Smith, Yun Dai, et al.. (2002). Synergistic Induction of Apoptosis in Human Myeloid Leukemia Cells by Phorbol 12-Myristate 13-Acetate and Flavopiridol Proceeds via Activation of Both the Intrinsic and Tumor Necrosis Factor-Mediated Extrinsic Cell Death Pathways. Molecular Pharmacology. 61(6). 1313–1321. 1 indexed citations

14.

Cartee, Leanne, Zhiliang Wang, Roy H. Decker, et al.. (2001). The cyclin-dependent kinase inhibitor (CDKI) flavopiridol disrupts phorbol 12-myristate 13-acetate-induced differentiation and CDKI expression while enhancing apoptosis in human myeloid leukemia cells.. PubMed. 61(6). 2583–91. 38 indexed citations

15.

Cartee, Leanne & Gregory L. Kucera. (2000). Protein Kinase C Modulation and Anticancer Drug Response. Cancer Investigation. 18(8). 731–739. 19 indexed citations

16.

Cartee, Leanne, Julie A. Vrana, Michael J. Birrer, et al.. (2000). Inhibition of the mitogen activated protein kinase pathway potentiates radiation-induced cell killing via cell cycle arrest at the G2/M transition and independently of increased signaling by the JNK/c-Jun pathway.. International Journal of Oncology. 16(2). 413–22. 22 indexed citations

17.

Cartee, Leanne & Gregory L. Kucera. (1998). Gemcitabine induces programmed cell death and activates protein kinase C in BG-1 human ovarian cancer cells. Cancer Chemotherapy and Pharmacology. 41(5). 403–412. 18 indexed citations

18.

Cartee, Leanne, Gregory L. Kucera, & Mark C. Willingham. (1998). Induction of apoptosis by gemcitabine in BG-1 human ovarian cancer cells compared with induction by staurosporine, paclitaxel and cisplatin. APOPTOSIS. 3(6). 439–449. 9 indexed citations

19.

Cartee, Leanne, et al.. (1998). The effects of gemcitabine and TPA on PKC signaling in BG-1 human ovarian cancer cells.. PubMed. 10(7). 371–7. 13 indexed citations

20.

Cartee, Leanne, William P. Petros, Gary L. Rosner, et al.. (1995). Evaluation of GM-CSF mouthwash for prevention of chemotherapy-induced mucositis: a randomized, double-blind, dose-ranging study. Cytokine. 7(5). 471–477. 55 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact